From Bench to Bedside: Immunotherapy for Prostate Cancer

The mainstay therapeutic strategy for metastatic castrate-resistant prostate cancer (CRPC) continues to be androgen deprivation therapy usually in combination with chemotherapy or androgen receptor targeting therapy in either sequence, or recently approved novel agents such as Radium 223. However, i...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Tse, Brian Wan-Chi, Jovanovic, Lidija, Nelson, Colleen Coyne, de Souza, Paul, Power, Carl Andrew, Russell, Pamela Joan
Format: Artigo
Idioma:Inglês
Publicat: Hindawi Publishing Corporation 2014
Matèries:
Review Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4168152/
https://ncbi.nlm.nih.gov/pubmed/25276838
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2014/981434
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars